<DOC>
	<DOCNO>NCT02748512</DOCNO>
	<brief_summary>A control , multi-center study evaluate utilization safety MK II inserter safety Fluocinolone Acetonide Intravitreal ( FAI ) insert subject non-infectious uveitis affect posterior segment eye .</brief_summary>
	<brief_title>A Controlled , Multi-center Study Utilization Safety MK II Inserter Safety FAI Insert Subjects With Non-infectious Uveitis Affecting Posterior Segment Eye</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<criteria>1 . Male nonpregnant female least 18 year age time consent 2 . At least one eye history noninfectious uveitis affect posterior segment 3 . Subject ability understand sign Informed Consent Form 4 . Subject willing able comply study requirement 1 . Allergy fluocinolone acetonide component FAI insert 2 . Ocular malignancy either eye , include choroidal melanoma 3 . Uveitis infectious etiology 4 . Current viral disease cornea conjunctiva include epithelial herpes simplex keratitis ( dendritic keratitis ) , vaccinia , varicella 5 . Current mycobacterial infection eye fungal disease ocular structure 6 . Subjects yield , screen , confirm positive test human immune deficiency virus ( HIV ) syphilis 7 . Systemic infection within 30 day prior study Day 1 8 . Peripheral retinal detachment area insertion 9 . Elevated intraocular pressure ( IOP ) &gt; 21 mmHg , chronic hypotony &lt; 6 mmHg 10 . Concurrent therapy Screening IOPlowering pharmacologic agent study eye 11 . Current diagnosis form glaucoma ocular hypertension study eye Screening , unless study eye previously treat incisional surgery procedure result stable IOP normal range ( 1021 mmHg ) 12 . Known history clinically significant IOP elevation response steroid treatment either eye , unless study eye previously treat incisional surgery procedure result stable IOP normal range ( 1021 mmHg ) 13 . Ocular surgery capsulotomy perform study eye within 30 day prior study Day 1 14 . Intravitreal treatment study eye : FAI insert within 36 month prior study Day 1 ; Retisert within 30 month prior study Day 1 ; Ozurdex within 90 day prior study Day 1 ; Triesence Trivaris within 30 day prior study Day 1 15 . Periocular subtenon steroid treatment study eye within 30 day prior study Day 1 16 . Treatment investigational drug device within 30 day prior study Day 1 , except FAI insert within protocol 17 . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method contraception outline protocol least 14 day prior study Day 1 Month 12 Visit 18 . Any condition , judgment Investigator , could make subject inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>